Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MNOV | 8-K | bullish | 5/10 | MediciNova terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville, effective September 8, 2026. The SEPA | Sep 2, 2026 |
| IRD | PRESS-RELEASE | neutral | 5/10 | Opus Genetics announced plans to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1 gene therapy on September 9, 202 | Sep 2, 2026 |
| CASIF | 6-K | bullish | 6/10 | CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics to BioMarin Pharmaceutical for approximately $5.9 | Sep 2, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma filed a 6-K announcing participation in the H.C. Wainwright 28th Annual Global Investment Conference (Sept | Sep 2, 2026 |
| FBRX | EFFECT | bearish | 6/10 | Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became effective on Septem | Sep 2, 2026 |
| TRIB | EFFECT | bullish | 6/10 | Trinity Biotech's F-1 registration statement (File No. 333-293717) became effective on September 1, 2026, enabling the c | Sep 2, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed two 6-Ks on September 2, 2026, each reporting a change in director's interest notice (one fo | Sep 2, 2026 |
| AVXL | DFAN14A | bullish | 7/10 | Activist investor PVG Asset Management has filed a definitive proxy statement and launched a shareholder website, formal | Sep 2, 2026 |
| FULC | S-4 | bearish | 7/10 | Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines | Sep 2, 2026 |
| VNRX | 8-K | bearish | 6/10 | VolitionRx issued 4,698,628 shares to Lind Global Asset Management XII LLC in satisfaction of $1,715,000 in conversion o | Sep 2, 2026 |
| PBM | EFFECT | neutral | 3/10 | Psyence Biomedical's shelf registration (F-3) on Form 333-298570 became effective on September 1, 2026. This allows the | Sep 2, 2026 |
| FBRX | EFFECT | bearish | 7/10 | Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) decl | Sep 2, 2026 |
| STLN | 8-K | neutral | 2/10 | Brad Hively, Vice Chairman of the Board, notified Starling Oncology of his decision not to stand for re-election at the | Sep 2, 2026 |
| QNTM | 6-K | neutral | 3/10 | Quantum BioPharma announced plans to voluntarily delist its Class B subordinate voting shares from the Canadian Securiti | Sep 2, 2026 |
| TLX | 6-K | bullish | 7/10 | Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for pros | Sep 2, 2026 |
| IMMP | 6-K | bearish | 7/10 | Immutep's FY2026 annual report confirms the devastating impact of the TACTI-004 Phase III trial discontinuation in March | Sep 2, 2026 |
| OMER | CLUSTER | neutral | 2/10 | Three OMER insiders (VP/General Counsel, Director, VP Finance) sold a combined ~$578K in open-market shares over a week, | Sep 2, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences (CEO, CCO, COO) sold shares totaling $878K over a week. The CEO's transacti | Sep 2, 2026 |
| FENC | CLUSTER | neutral | 4/10 | Two C-suite insiders at Fennec Pharmaceuticals (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day w | Sep 2, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Three CYTK insiders (CEO, EVP, Director) sold a total of $1.59M in open-market shares over a 7-day window, primarily fro | Sep 2, 2026 |
| SNY | COURT-RULING | neutral | 2/10 | The District of Oregon adopted a magistrate judge's recommendation and dismissed with prejudice a lawsuit against Sanofi | Sep 1, 2026 |
| QNRX | CLUSTER | mixed | 6/10 | Three insiders at Quoin Pharmaceuticals (CEO, CFO, and a Director) made open-market purchases totaling $180K at $4.88/sh | Sep 1, 2026 |
| ASND | ANALYST-UPGRADE | bullish | 4/10 | HC Wainwright & Co. initiated coverage on Ascendis Pharma A/S (ASND) at Buy with a price target of $345, implying 31% up | Sep 1, 2026 |
| ROIV | CLUSTER | neutral | 3/10 | Two senior Roivant executives (President & CIO Mayukh Sukhatme and President & Immunovant CEO Eric Venker) sold a combin | Sep 1, 2026 |
| MRNA | COURT-RULING | bearish | 6/10 | A federal magistrate judge granted plaintiff's motion to strike several key exhibits that Moderna had submitted in suppo | Sep 1, 2026 |
| ORKA | CLUSTER | bearish | 4/10 | Oruka Therapeutics CEO Lawrence Klein and COO Laura Sandler sold a combined $5.94M in open-market stock on September 1, | Sep 1, 2026 |
| QNTM | PRESS-RELEASE | neutral | 3/10 | Quantum BioPharma (QNTM) announced it has applied for a voluntary delisting from the Canadian Securities Exchange (CSE), | Sep 1, 2026 |
| XERS | CLUSTER | neutral | 3/10 | Three Xeris Biopharma insiders (McCulloch, Hecht, Pieper) sold a combined $311K in open-market shares on September 1, 20 | Sep 1, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prosta | Sep 1, 2026 |
| ANIP | CLUSTER | neutral | 3/10 | Two top ANIP executives, CEO Nikhil Lalwani and CFO Stephen Carey, collectively sold $609K in open-market shares within | Sep 1, 2026 |